Evidence map›Paper›PMID 25013513›Full record

ArticleOncology letters2014

Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report.

Lijuan Han, Mingzhi Zhang, Ling Li, Lei Zhang, Jingjing Wu, Xin Li, Xinhua Wang, Ken H Young, Xiaorui Fu, Wang Ma and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Lijuan HanDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
Mingzhi ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
Ling LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
Lei ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
Jingjing WuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
Xin LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
Xinhua WangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
Ken H YoungDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77230-1439, USA.
Xiaorui FuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
Wang MaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
Zhenchang SunDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
Xudong ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
Yu ChangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
Zhi QiaoDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ; Lymphoma Diagnosis and Treatment Center, Zhengzhou, Henan 450052, P.R. China.
First Affiliated Hospital of Zhengzhou University · CNThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK)/T-cell lymphoma-associated hemophagocytic syndrome (HPS) is a rare and fatal disease with no optimal treatment. The present study reports the clinical features, diagnosis and treatment process of three patients with relapsed NK/T-cell lymphoma-associated HPS. All of the patients were classified as Ann Arbor stage IV and presented with a poor performance status. Two patients were successfully treated with a pegaspargase-containing combination regimen and one patient succumbed due to serious complications. These cases indicate that for patients with a history of lymphoma, the diagnosis of HPS should be considered when patients present with progressive high fever, pancytopenia and liver dysfunction. Early identification and effective treatments, including pegaspargase-based regimens are essential for an enhanced prognosis.

Indexed as

clinical featureshemophagocytic syndromenatural killer/T-cell lymphomapegaspargase

Identifiers

PMID25013513
PMCPMC4081409
OpenAlexW2084969658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.